Schrödinger (NASDAQ:SDGR) Posts Earnings Results

Schrödinger (NASDAQ:SDGR) announced its earnings results on Wednesday. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20), Zacks reports. The firm had revenue of $88.32 million for the quarter, compared to the consensus estimate of $83.20 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. Schrödinger updated its FY 2025 guidance to EPS.

Schrödinger Stock Up 6.8 %

Shares of Schrödinger stock traded up $1.48 during trading on Thursday, hitting $23.18. The stock had a trading volume of 824,864 shares, compared to its average volume of 998,625. Schrödinger has a 1 year low of $16.67 and a 1 year high of $32.46. The stock has a 50 day simple moving average of $22.23 and a 200 day simple moving average of $20.56. The company has a market capitalization of $1.69 billion, a PE ratio of -10.07 and a beta of 1.61.

Analyst Upgrades and Downgrades

SDGR has been the topic of a number of research reports. KeyCorp boosted their price objective on Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. BMO Capital Markets upped their price target on shares of Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Piper Sandler reduced their price objective on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.56.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.